Ann: 2024 Full Year Results webinar, page-67

Had forgotten about COVID, good point. I hope you're right but cutting it to 1.5 years would still take us to the start of 2027. Sorry wrote this before I saw your reply).

To me a big factor for some will be where the share price goes between now and the read out. If you're in the camp of 2591 is a home run. No way it can fail Ph3 then you should be using this time as a chance to accumulate and build on current holdings. The share price will be multiples of where it is now with positive Ph3 results. At the opposite end would be anyone who has no intention of sitting through such a binary decision point as a clinical trial readout and will be looking at maximising their gains before cashing out prior to that event. And like most things there is the majority in-between who realise that there is less than a 100% chance of the trial succeeding and will want to mitigate their risk accordingly by selling some prior to the results. In that case it matters a lot where the share price goes between now and then and that's where Acadia's ability to reinvigorate Daybue sales growth will help a lot as well as continually growing the story of 2591 as a platform drug. Not sure what will eventuate on these fronts and how the broader global economic situation is faring is always a factor.

One thing that would no doubt push the price back up quickly is if the market believes there is a solid takeover/licensing bid in the mix. Jon and Co are thankfully of high morals and behave impeccably when it comes to corporate responsibility. They won't 'leak' non-genuine offers but are compelled to present strong, genuine ones and missing out on that kind of announcement could be very costly.

So fun times ahead I think. So much upside from here and at times it may feel like an interminable wait but I'm confident it will be well worth it. Seeing Mel's updates on Katelin along the way and the growing body of remarkable success stories makes it all the more rewarding too.